Cladribine injection is a specialized pharmaceutical formulation used primarily in the treatment of hairy cell leukemia, a rare type of chronic leukemia affecting B-cell lymphocytes. This medication acts as a purine nucleoside analog, disrupting DNA synthesis and repair, thereby inducing cell death in malignant lymphocytes. Administered under strict medical supervision, Cladribine injection is effective in targeting and reducing leukemic cell populations, leading to remission in many patients. Its application requires careful dosage calculation and monitoring due to potential side effects and immunosuppressive effects during therapy.
Key Features
| Features | Description |
|---|---|
| Active Ingredient | Cladribine |
| Therapeutic Use | Treatment of Hairy Cell Leukemia |
| Formulation | Injectable Solution |
| Mechanism of Action | Purine nucleoside analog that inhibits DNA synthesis in malignant cells |
| Administration Route | Intravenous injection |
| Dosage Form | Injection vial |
| Clinical Effect | Reduces leukemic B-cells, induces remission |
| Storage Conditions | Store in a cool, dry place, protected from light |
| Handling Precautions | Requires administration by healthcare professionals under controlled conditions |
| Attributes | Description |
|---|---|
| Concentration | Approximately 2 mg/mL (dependent on formulation) |
| Packaging | Single-use vials |
| Shelf Life | Typically 24 months from manufacturing |
| Compatibility | Compatible with sterile intravenous fluids |
| Storage Temperature | 2°C to 8°C (Refrigerated) |
| Pharmacological Classification | Antineoplastic agent |
| Preservatives | Preservative-free formulation recommended |
| Administration Frequency | Typically administered over 5 to 7 days in cycles as per oncologist prescription |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
Cladribine injection is primarily indicated for patients diagnosed with hairy cell leukemia and is typically administered following a detailed evaluation by an oncologist. Its safety and efficacy depend on the disease stage and patient's overall health.
Healthcare professionals must ensure proper sterile techniques during administration, monitor patient blood counts regularly due to potential immunosuppression, and manage side effects carefully throughout the treatment cycle.
Dosage is individualized based on patient weight, kidney function, and overall health status, following established clinical guidelines to optimize efficacy while minimizing toxicity.
Yes, Cladribine injection must be stored refrigerated between 2°C and 8°C and protected from light to maintain its stability and effectiveness.
While primarily used alone for hairy cell leukemia, Cladribine may be combined with other therapies as determined by medical oncologists based on patient-specific factors.
Country Of Origin: India
Cladribine is used in the treatment of hairy cell leukemia.
